Amyotrophic Lateral Sclerosis (ALS) Clinical Trials

A listing of Amyotrophic Lateral Sclerosis (ALS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.

primary lateral sclerosis
edaravone
  • 0 views
  • 28 Jul, 2021
  • 34 locations
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis

primary lateral sclerosis
  • 0 views
  • 31 Jul, 2021
  • 19 locations
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating ScaleRevised

primary lateral sclerosis
edaravone
  • 0 views
  • 01 Aug, 2021
  • 47 locations
Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)

The objective of this trial is to assess the efficacy, safety, and PK/PD effects of CNM-Au8 as a disease-modifying agent for the treatment of ALS by utilizing electrophysiological measures to detect preservation of motor neuron function. The primary endpoint is the mean change in the average difference between active treatment …

primary lateral sclerosis
riluzole
  • 17 views
  • 30 Jul, 2021
  • 2 locations
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Background Some people with Amyotrophic Lateral Sclerosis (ALS) have a high level of the virus HERV-K in their blood. Researchers do not think this virus causes

primary lateral sclerosis
edaravone
riluzole
  • 80 views
  • 01 Aug, 2021
  • 1 location
Trial of Safety Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.

primary lateral sclerosis
riluzole
  • 7 views
  • 01 Aug, 2021
  • 1 location
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of intrathecal (IT) WVE-004 in adult patients with C9orf72-associated ALS or FTD. To participate in the study, patients must have a documented mutation (GGGGCC [G4C2] repeat expansion) in the first intronic region …

amyotrophic lateral sclerosis
frontotemporal lobar degeneration
dementia
frontotemporal dementia
primary lateral sclerosis
  • 0 views
  • 31 Jul, 2021
  • 2 locations
RAPA-501 Therapy for ALS

RAPA-501-ALS is an open-label, dose escalation, Phase 1/2 study of RAPA-501 autologous T cells in adults with amyotrophic lateral sclerosis (ALS).

radicava
tendency to bleed
familial amyotrophic lateral sclerosis
primary lateral sclerosis
edaravone
  • 0 views
  • 01 Aug, 2021
  • 2 locations
New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new

primary lateral sclerosis
spinal cord
  • 0 views
  • 26 Jul, 2021
  • 1 location
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

swallow study
weakness
pulmonary function test
edaravone
ibudilast
  • 57 views
  • 20 Jul, 2021
  • 19 locations